Philadelphia Trust Co Lowers stake in Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX) : Philadelphia Trust Co reduced its stake in Quest Diagnostics Inc by 16.83% during the most recent quarter end. The investment management company now holds a total of 307,185 shares of Quest Diagnostics Inc which is valued at $26,353,401 after selling 62,170 shares in Quest Diagnostics Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Quest Diagnostics Inc makes up approximately 2.16% of Philadelphia Trust Co’s portfolio.

Other Hedge Funds, Including , Fdo Partners boosted its stake in DGX in the latest quarter, The investment management firm added 5,148 additional shares and now holds a total of 24,320 shares of Quest Diagnostics Inc which is valued at $2,086,413. Quest Diagnostics Inc makes up approx 1.08% of Fdo Partners’s portfolio.Finemark National Bank Trust reduced its stake in DGX by selling 324 shares or 23.14% in the most recent quarter. The Hedge Fund company now holds 1,076 shares of DGX which is valued at $92,601. Quest Diagnostics Inc makes up approx 0.01% of Finemark National Bank Trust’s portfolio. Trillium Asset Management added DGX to its portfolio by purchasing 17,625 company shares during the most recent quarter which is valued at $1,522,095. Quest Diagnostics Inc makes up approx 0.10% of Trillium Asset Management’s portfolio.

Quest Diagnostics Inc opened for trading at $83 and hit $84.56 on the upside on Monday, eventually ending the session at $84.33, with a gain of 1.63% or 1.35 points. The heightened volatility saw the trading volume jump to 11,97,025 shares. Company has a market cap of $11,723 M.

On the company’s financial health, Quest Diagnostics Inc reported $1.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $1.32. The company had revenue of $1906.00 million for the quarter, compared to analysts expectations of $1905.57 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.25 EPS.

Investors should note that on Aug 17, 2016, Quest Diagnostics Inc announced a cash dividend of $0.4000. The company’s management has announced Sep 30, 2016 as the ex-dividend date and fixed the record date on Oct 4, 2016. The payable date has been fixed on Oct 19, 2016.

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Company’s other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Quest Diagnostics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quest Diagnostics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.